Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial
- 2 November 2004
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 44 (9), 1792-1800
- https://doi.org/10.1016/j.jacc.2004.05.085
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trialsAmerican Heart Journal, 2003
- Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary InterventionJAMA, 2003
- Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventionsJournal of the American College of Cardiology, 2003
- Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary interventionJournal of the American College of Cardiology, 2001
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialThe Lancet, 2000
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Economic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary AngioplastyCirculation, 1996
- In-Hospital and One-Year Economic Outcomes After Coronary Stenting or Balloon AngioplastyCirculation, 1995
- In-Hospital Cost of Percutaneous Coronary RevascularizationCirculation, 1995